Dr. Reddy's Laboratories Limited

“Dr. Reddy's is a structurally sound Indian pharma operator with a credible upgrade path from commodity generics toward branded India and biosimilars, a net-cash balance sheet, and improving returns — but it is not an exceptional business. US generic price deflation is a permanent structural headwind, FDA compliance risk represents the sole but credible pathway to permanent impairment, and 24x forward earnings leaves essentially no margin of safety for a business with this risk profile. The 2-3x decade return is plausible but demands a cheaper entry and resolution of tail risks.”